Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?

Moderna stock has surged 109% in 2026 as the biotech company successfully transitions from a coronavirus vaccine player to a multi-product company. With cost reductions of 26%, three approved products, and promising late-stage candidates in oncology and rare diseases, analysts view it as increasingly investable. Though the stock has pulled back 24% from its July peak, it remains a buy for long-term investors, though cautious investors may wait for further progress on pipeline candidates.